HomeAI · summaries
Storia in 3 fonti
Drugmakers don’t have ‘duty to innovate’, California court rules, backing Gilead in HIV drug litigation
Years of litigation surrounding Gilead Sciences’ tenofivor-based HIV treatments have come to an end, with the California Supreme Court taking Gilead’s side in a ruling that sets a key precedent for | Years of litigation surrounding Gilead Sciences’ tenofivor-based HIV treatments have come to an end, with the California Supreme Court taking Gilead’s side in a ruling that sets a key precedent for innovative drugmakers.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims
’Tis the season to resolve long-standing litigation in the U.S. | A week after Johnson & Johnson moved to resolve claims that its Johnson’s Baby Powder caused ovarian cancer,…
- ·
www1.folha.uol.com.br
Justiça dos EUA decide a favor da Gilead e conclui que farmacêuticas não têm dever de inovar
Ação movida por pacientes questionava a interrupção de um novo remédio para HIV com menos efeitos colaterais
